Talphera (NASDAQ:TLPH) Raised to “Hold” at Zacks Research

Talphera (NASDAQ:TLPH) was upgraded by analysts at Zacks Research to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. HC Wainwright assumed coverage on shares of Talphera in a research report on Friday, June 5th. They set a “buy” rating and a $3.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. Finally, Westpark Capital assumed coverage on shares of Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.00.

Talphera Trading Down 3.7%

Shares of NASDAQ:TLPH opened at $0.82 on Monday. The company has a 50 day moving average of $0.81 and a 200 day moving average of $0.94. The stock has a market cap of $42.33 million, a P/E ratio of -2.63 and a beta of 0.76. Talphera has a 12 month low of $0.38 and a 12 month high of $1.57.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. On average, equities analysts forecast that Talphera will post -0.26 earnings per share for the current fiscal year.

Insider Transactions at Talphera

In related news, CEO Vincent J. Angotti bought 213,310 shares of the company’s stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the completion of the transaction, the chief executive officer directly owned 800,705 shares in the company, valued at $472,415.95. This trade represents a 36.31% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Talphera

Hedge funds have recently made changes to their positions in the business. Group One Trading LLC lifted its holdings in shares of Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Talphera in the 3rd quarter worth approximately $29,000. Persistent Asset Partners Ltd bought a new stake in shares of Talphera in the 4th quarter worth approximately $42,000. Mariner LLC lifted its holdings in shares of Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after acquiring an additional 33,000 shares during the last quarter. Finally, Dauntless Investment Group LLC bought a new stake in shares of Talphera in the 3rd quarter worth approximately $89,000. 37.67% of the stock is currently owned by institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.